Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum

Corporate Breaking News

Home : Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum

Oct 02 2019	Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
EAST HANOVER, N.J., Oct. 2, 2019 /PRNewswire/ -- Novartis, a leader in rheumatology and immuno-dermatology, today announced additional positive data from the PREVENT trial, evaluating the efficacy and safety of Cosentyx® (secukinumab) in patients with non-radiographic axial...


Source:https://www.prnewswire.com:443/news-releases/novartis-positive-52-week-prevent-data-confirm-cosentyx-efficacy-in-addressing-entire-axspa-spectrum-300929426.html

Related News
» Chiffre d'affaires mondial de PwC en hausse de 7 % [1] à 42,4 milliards USD » BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting